Effect of Renin-Angiotensin System Blockade on Soluble Klotho in Patients with Type 2 Diabetes, Systolic Hypertension, and Albuminuria

Janaka Karalliedde, Giuseppe Maltese, Benjamin Hill, Giancarlo Viberti, and Luigi Gnudi

Summary

Background and objectives Soluble Klotho is an anti-aging phosphaturic protein associated with vascular-renal protection. In vitro and in vivo studies have demonstrated that renin-angiotensin system (RAS) blockade increases soluble Klotho levels. The effect of RAS blockers on soluble Klotho in patients with diabetic kidney disease (DKD) is unknown.

Design, setting, participants, & measurements Plasma-soluble Klotho was measured in a secondary analysis of a randomized controlled clinical trial performed at a single university hospital center (ClinicalTrials.gov number NCT001715, from March 2003 to September 2006). Seventy-six patients with type 2 diabetes and DKD (all with albuminuria and serum creatinine <1.7 mg/dl) were studied at baseline and at 24 weeks (study end) after randomization to valsartan/hydrochlorothiazide (n=37) or amlodipine (n=39) treatment. Aortic-pulse wave velocity by applanation tonometry and albuminuria (from three timed urine collections) were also measured at baseline and 24 weeks.

Results Valsartan/hydrochlorothiazide treatment significantly increased mean (± SD) soluble Klotho (from 432.7±179 to 506.4±226.8 pg/ml; P=0.01) and reduced serum phosphate (from 3.25±1.18 to 2.60±0.96 mg/dl; P=0.04) compared with amlodipine (from 430.1±145.8 to 411.9±157.6 pg/ml and from 2.94±0.56 to 2.69±1.52 mg/dl, respectively). There was a significant difference between treatment groups in soluble Klotho (mean 91.9 pg/ml; 95% confidence interval, 19.9 to 162) and serum phosphate levels (mean −0.68 mg/dl; 95% confidence interval, −0.15 to −1.33) with valsartan/hydrochlorothiazide treatment (P=0.03 and P=0.04, respectively). Attained BP was similar in the two groups and levels of soluble Klotho were not associated with aortic-pulse wave velocity and albuminuria, variables that fell significantly only with valsartan/hydrochlorothiazide.

Conclusion Treatment with a RAS blocker, valsartan, is associated with an increase in soluble Klotho, which may contribute to the BP-independent cardiorenal benefits of these drugs in DKD.


Introduction

Klotho is an aging-suppressor gene encoding a transmembrane protein with an extracellular portion, and is predominantly expressed in the distal renal tubules and in the circulation as a soluble isoform (1,2). This membrane-bound protein works in conjunction with fibroblast growth factor 23 (FGF-23), a bone-derived hormone that regulates urinary phosphate excretion (2–4). The circulating form of Klotho (molecular mass of 130 kD), detectable in plasma and urine, is named soluble or cleaved Klotho.

Soluble (cleaved) Klotho is derived from the proteolytic cleavage of the extracellular portion of the membrane-bound Klotho and consists of two internal repeats, known as KL1 and KL2, respectively. KL1 (molecular mass of 68–70 kD) may be produced through alternative mRNA splicing, but its biologic role is unclear.

In mice, the deletion of the Klotho gene is associated with shortened lifespan, derangement of phosphorus regulation, renal fibrosis, and vascular calcification. There is emerging evidence that soluble Klotho may have biological effects in addition to the transmembrane form because the exogenous replacement of soluble Klotho restores a normal phenotype in Klotho mutant mice (1,2,4). Soluble Klotho confers vascular-renal protection in different experimental models of metabolic and kidney diseases by enhancing antioxidant, antisenescence, and antiapoptotic mechanisms (1,2). Angiotensin II (AngII), a proinflammatory and oxidant agent, is upregulated in a variety of kidney diseases, including diabetic kidney disease. In animal models of kidney disease, AngII decreases renal Klotho expression and this downregulation is prevented by an angiotensin type I receptor blocker (ARB) (5,6).

The effect of an ARB on soluble Klotho, FGF-23, and serum phosphate in humans—specifically, in patients with type II diabetes mellitus, systolic hypertension, and albuminuria—is unknown. Our hypothesis was...
that an ARB, compared with a calcium channel blocker, would significantly increase soluble Klotho levels in a BP-

independent manner in patients with type II diabetes mel-

litus, systolic hypertension, and albuminuria.

Materials and Methods

Patients with type II diabetes mellitus with systolic hypertension and albuminuria were recruited as previ-

ously described to a single-center double-blind random-

ized controlled study (ClinicalTrials.gov registry number NCT00171561 between March 2003 and September 2006) (7). In brief, patients with type II diabetes mellitus were eligible if they were aged between 40 and 80 years with a recorded history of elevated albumin excretion rate (AER) (albumin/creatinine ratio \( \geq 22 \) mg/g in men and \( \geq 31 \) mg/g in women on \( >3 \) occasions and/or AER \( \geq 20 \) \( \mu \)g/min on at least two timed overnight urine collections) and systolic hypertension defined as brachial systolic BP (SBP) \( \geq 140 \) mmHg and pulse pressure (PP) \( \geq 60 \) mmHg (a conservative PP criterion for the diagnosis of isolated systolic hyperten-

sion) (7). Exclusion criteria included clinical or biochemical evidence of renal impairment (creatinine \( >1.7 \) mg/dl), uncontrolled diabetes defined as fasting plasma glucose \( >200 \) mg/dl or hemoglobin A1c (HbA1c) \( >10\% \), presence of connective tissue diseases known to affect arterial vasculature, atrial fibrillation or other cardiac rhythm disor-

ders, history of nondiabetic or obstructive kidney disease, microscopic or macroscopic hematuria, pregnancy, and his-

tory of a cardiovascular or cerebrovascular event in the preceding 12 months.

Patients receiving antihypertensive agents for systolic hypertension were permitted into the trial. BP medications

were stopped for a wash-out, run-in phase of 4 weeks, during which all patients received moxonidine (400 \( \mu \)g/d), a central selective imidazoline receptor agonist. Moxonidine has a minimal effect on vessel wall properties and was used to avoid uncontrolled hypertension (SBP \( \geq 180 \) mmHg) (8). At the end of the run-in period, patients with brachial PP \( \geq 60 \) mmHg and SBP \( \geq 140 \) mmHg were randomized to receive 160 mg of valsartan or 5 mg of amloidipine and moxonidine was discontinued. After 4 weeks, a dosage of 25 mg/d of hydrochlorothiazide was added to valsartan and amloidipine was uptitrated to 10 mg. Hydrochlorothi-

azide was added to 160 mg of valsartan (the maximum dose licensed for use in the United Kingdom) to ensure equivalent BP lowering between the treatment arms. Hy-

drochlorothiazide has no significant effect on arterial wall properties (9). The use of other antihypertensive agents was not permitted during the trial because they could interfere with study evaluations and interpretation of results.

All measurements and procedures were performed with the patients in the fasted state and having refrained from nicotine, alcohol, and caffeine for at least the previous 10 hours.

Plasma-soluble Klotho (IBL Co. Ltd., Minneapolis, MN) and plasma C-terminal FGF-23 (Immunotopics Inc., San Clemente, CA) were measured in duplicate by ELISA from samples collected at baseline and at the end of the 24 weeks of treatment and were stored at \( -80^\circ C \). Serum phosphate was measured in duplicate by spectrophotometry (Pointe Scientific Inc., Canton, MI). The intra-assay and interassay coefficients of variation for soluble Klotho and FGF-23 ELISA were 2.7\% and 6.5\% and 4.4\% and 6.1\%, respectively (10).

The assay we utilized for measuring soluble Klotho has been used in many clinical and experimental studies and in a range of patients and animal models of disease (4,10–13).

The soluble Klotho assay used in our study and other studies to date measures the larger 130 kD cleaved protein. A smaller fragment of 68–70 kD, as a result of alternative mRNA splicing (2), of current unknown significance may be present in the circulation, but is not detected by this assay.

Aortic-pulse wave velocity (Ao-PWV) was determined from carotid and femoral pressure waveforms obtained noninvasively by applanation tonometry (Millar tonome-

ter; Millar Instruments, Houston, TX) using the Sphygmom-

Cor system (Atcor, Sydney, Australia) as previously described (7). The within-subject SD of Ao-PWV assessed using this method in our laboratory was 0.5 m/s and the intraobserver and interobserver coefficients of variation were 3.0\% and 3.5\%, respectively (7). Albumin concentra-

tion was measured by immunoturbidimetry using a Cobas Miras Plus analyzer (Roche Diagnostics, Basel, Switzerland) and AER was calculated from the median of three noncon-

secutive timed overnight urine specimens collected 1 week before Ao-PWV measurement (7).

Two-sample \( t \) tests (paired) were conducted to compare variables in each group at baseline and at the study end, whereas comparison between groups was conducted with an independent sample \( t \) test. AER and FGF-23 data were log-transformed before parametric tests. A multivariate linear regression analysis was performed to determine which independent variables were associated with change in soluble Klotho levels (the dependent variable). All sta-

tistical analyses were performed using SPSS software (ver-

sion 17; SPSS Inc., Chicago, IL). All measurements and statistical analyses were performed blinded to treatment groups.

All patients were recruited from the Diabetes Clinic at Guy’s and St Thomas’ Hospitals (London, UK) and provided written informed consent to participate in the study, which was approved by the research ethics committee of Guy’s and St Thomas’ Hospitals and undertaken in adher-

tence to the Declaration of Helsinki.

Results

Of the 103 patients who completed the primary study, 76 patients had samples available for measurement of soluble Klotho. The baseline clinical and biochemical character-

istics of the 27 patients who did not have samples available for analyses were not significantly different from the 76 patients studied.

There were no significant baseline differences between the two groups in terms of sex (men comprised 60\% of both groups) or ethnic distribution. Selected baseline clinical and biochemical data are shown in Table 1. All patients had serum creatinine <1.41 mg/dl and esti-

mated GFR (eGFR) >45 ml/min per 1.73 m\(^2\) calculated by the four-variable Modified Diet in Renal Disease for-

mula. Prior use of antihypertensive drugs was similar in
the two groups. The frequency and number of antidiabetic, antiplatelet, and lipid-lowering agents were also similar in the two groups. No patients were taking vitamin D treatment or phosphate binders or calcium or phosphate supplements.

Table 1. Baseline selected clinical and biochemical data for 76 patients with type II diabetes mellitus, systolic hypertension, and albuminuria randomized to valsartan and hydrochlorothiazide or amlodipine treatment

<table>
<thead>
<tr>
<th>Variable</th>
<th>Valsartan/Hydrochlorothiazide (n=37)</th>
<th>Amlodipine (n=39)</th>
<th>Valsartan/Hydrochlorothiazide versus Amlodipine (P Value)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (yr)</td>
<td>60.3±8.5</td>
<td>59.3±10.2</td>
<td>0.64</td>
</tr>
<tr>
<td>Duration of diabetes (yr)</td>
<td>10.8±7.5</td>
<td>10.1±6.7</td>
<td>0.76</td>
</tr>
<tr>
<td>Body mass index (kg/m²)</td>
<td>31.4±5.5</td>
<td>31.9±5.6</td>
<td>0.88</td>
</tr>
<tr>
<td>Brachial SBP (mmHg)</td>
<td>155.5±10.8</td>
<td>159.5±10.7</td>
<td>0.09</td>
</tr>
<tr>
<td>Brachial DBP (mmHg)</td>
<td>80.3±9.6</td>
<td>81.9±9.4</td>
<td>0.42</td>
</tr>
<tr>
<td>HbA1c (%) (mmol/mol)</td>
<td>7.1 (54)±1.0 (11)</td>
<td>7.6 (60)±1.1 (12)</td>
<td>0.34</td>
</tr>
<tr>
<td>Total cholesterol (mg/dl)</td>
<td>169.9±34.7</td>
<td>162.2±38.6</td>
<td>0.72</td>
</tr>
<tr>
<td>Serum creatinine (mg/dl)</td>
<td>0.92±0.20</td>
<td>0.95±0.22</td>
<td>0.64</td>
</tr>
<tr>
<td>eGFR (ml/min per 1.73 m²)</td>
<td>92.3±21.6</td>
<td>96.7±23.9</td>
<td>0.40</td>
</tr>
<tr>
<td>UAER (µg/min)</td>
<td>31 (18–90)</td>
<td>25 (14–60)</td>
<td>0.76</td>
</tr>
</tbody>
</table>

Data are presented as the mean ± SD or median (interquartile range) unless otherwise stated. SBP, systolic BP; DBP, diastolic BP; Ao-PWV, aortic-pulse wave velocity; HbA1c, hemoglobin A1c; eGFR, estimated GFR; UAER, urine albumin excretion rate.

Table 2. Selected data from baseline and study end for 76 patients with type II diabetes mellitus, systolic hypertension, and albuminuria randomized to valsartan and hydrochlorothiazide or amlodipine treatment

<table>
<thead>
<tr>
<th>Variable</th>
<th>Valsartan/Hydrochlorothiazide (n=37)</th>
<th>Amlodipine (n=39)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Soluble Klotho (pg/ml)</td>
<td>432.7±179.0</td>
<td>430.1±145.8</td>
</tr>
<tr>
<td>Baseline</td>
<td>432.7±179.0</td>
<td>430.1±145.8</td>
</tr>
<tr>
<td>Study end</td>
<td>506.4±226.8</td>
<td>411.9±157.6</td>
</tr>
<tr>
<td>Change from baseline (95% CI)</td>
<td>73.7 (19.2 to 128.2)</td>
<td>−18.3 (−29.0 to 65.6)a</td>
</tr>
<tr>
<td>P value</td>
<td>0.01</td>
<td>0.43</td>
</tr>
<tr>
<td>Serum phosphate (mg/dl)</td>
<td>3.25±1.18</td>
<td>2.94±0.56</td>
</tr>
<tr>
<td>Baseline</td>
<td>3.25±1.18</td>
<td>2.94±0.56</td>
</tr>
<tr>
<td>Study end</td>
<td>2.60±0.96</td>
<td>2.69±1.52</td>
</tr>
<tr>
<td>Change from baseline (95% CI)</td>
<td>−0.65 (−0.09 to −1.33)</td>
<td>0.22 (−0.03 to 0.90)a</td>
</tr>
<tr>
<td>P value</td>
<td>0.04</td>
<td>0.44</td>
</tr>
<tr>
<td>Log FGF-23 (RU/ml)</td>
<td>1.21±0.18</td>
<td>1.31±0.23</td>
</tr>
<tr>
<td>Baseline</td>
<td>1.21±0.18</td>
<td>1.31±0.23</td>
</tr>
<tr>
<td>Study end</td>
<td>1.32±0.21</td>
<td>1.29±0.24</td>
</tr>
<tr>
<td>Change from baseline (95% CI)</td>
<td>0.11 (0.02 to 0.19)</td>
<td>−0.02 (−0.05 to 0.09)</td>
</tr>
<tr>
<td>P value</td>
<td>0.01</td>
<td>0.55</td>
</tr>
<tr>
<td>Brachial pulse pressure (mmHg)</td>
<td>76.6±11.5</td>
<td>74.1±9.7</td>
</tr>
<tr>
<td>Baseline</td>
<td>76.6±11.5</td>
<td>74.1±9.7</td>
</tr>
<tr>
<td>Study end</td>
<td>61.5±13.3</td>
<td>61.0±10.2</td>
</tr>
<tr>
<td>Change from baseline (95% CI)</td>
<td>−15.1 (−12.4 to −17.8)</td>
<td>−13.1 (−10.0 to −16.2)</td>
</tr>
<tr>
<td>P value</td>
<td>&lt;0.001</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Ao-PWV (m/s)</td>
<td>12.4±2.4</td>
<td>12.2±2.7</td>
</tr>
<tr>
<td>Baseline</td>
<td>12.4±2.4</td>
<td>12.2±2.7</td>
</tr>
<tr>
<td>Study end</td>
<td>10.7±2.8</td>
<td>11.8±2.8</td>
</tr>
<tr>
<td>Change from baseline (95% CI)</td>
<td>−1.7 (−2.3 to −1.1)</td>
<td>−0.5 (−1.3 to 0.04)a</td>
</tr>
<tr>
<td>P value</td>
<td>&lt;0.001</td>
<td>0.22</td>
</tr>
</tbody>
</table>

Data are presented as the mean ± SD unless otherwise stated. 95% CI, 95% confidence interval; FGF-23, fibroblast growth factor 23; Ao-PWV, aortic-pulse wave velocity; FGF-23, fibroblast growth factor 23. aP<0.05 between treatment groups.
group (from \(430.1 \pm 145.8\) to \(411.9 \pm 157.6\) pg/ml; \(P=0.04\)), with a significant mean difference of \(91.9\) pg/ml between treatment groups (95% confidence interval [95% CI], 19.9 to 162; \(P=0.03\); Figure 1). Concomitantly, phosphate levels fell significantly only in the valsartan/hydrochlorothiazide group (from \(3.25 \pm 1.18\) to \(2.60 \pm 0.96\) mg/dl; \(P=0.04\)), with a significant mean difference of \(-0.68\) mg/dl between treatment groups (95% CI, \(-1.15\) to \(-1.33\); \(P=0.04\); Figure 1). In the valsartan/hydrochlorothiazide group, change in soluble Klotho was negatively correlated with change in phosphate (Pearson correlation \(R^2=-0.41\); \(P=0.07\)) but did not reach the conventional level of statistical significance.

FGF-23 levels increased significantly, albeit very modestly, from a median of \(17.2\) RU/ml (interquartile range [IQR], 11.7–24.9) to \(21.9\) RU/ml (IQR, 13.0–39.0) with valsartan/hydrochlorothiazide treatment (\(P=0.01\)) compared with no significant change observed with amlodipine treatment, which changed from a median of \(19.2\) RU/ml (IQR, 12.8–23.5) to \(18.5\) RU/ml (IQR, 13.2–22.8) with no significant difference between treatment groups. Log-transformed FGF-23 data are shown in Table 2.

Renal function and serum creatinine remained stable during the study, with no significant reduction or differences between the two groups at the study end. There was no significant baseline difference in corrected serum calcium levels between the two groups (9.44±0.40 versus 9.40±0.44 mg/dl; \(P=0.73\)) or change in serum calcium levels during the study (data not shown). Changes in soluble Klotho, phosphate, or FGF-23 were not significantly associated with changes in Ao-PWV, BP, or albuminuria.

There were no statistically significant correlations between changes in Klotho levels with Ao-PWV (\(R^2=0.12; P=0.54\)) or albuminuria (\(R^2=-0.17; P=0.37\)) observed in the valsartan/hydrochlorothiazide group, in which there was a significant reduction in Ao-PWV and albuminuria. In a multivariate regression analysis model, valsartan/hydrochlorothiazide treatment was the only variable significantly associated with the change in serum Klotho levels (SD change of soluble Klotho: standardized coefficient \(\beta=0.29; P=0.04\)). The following variables were also entered into the multivariate model: age, duration of diabetes, baseline PP, and AER; however, none of these variables were significantly associated with change in soluble Klotho.

Ao-PWV fell significantly from \(12.4 \pm 2.4\) m/s to \(10.7 \pm 2.8\) m/s in the valsartan/hydrochlorothiazide group, with a mean change of \(-1.7\) m/s from baseline (95% CI, \(-2.3\) to \(-1.1\); \(P<0.001\)). In contrast, there was no statistically significant reduction observed in the amlodipine group (from \(12.2 \pm 2.7\) to \(11.8 \pm 2.8\) m/s), with a mean change of \(-0.5\) from baseline m/s (95% CI, \(-1.3\) to \(-0.4\); \(P=0.22\)). PP fell significantly and similarly by a mean of \(-15.1\) mmHg (95% CI, \(-17.8\) to \(-12.4\)) and a mean of \(-13.1\) mmHg (95% CI, \(-16.2\) to \(-10.0\)) with valsartan/hydrochlorothiazide and amlodipine, respectively, with no between-group difference.

Albuminuria fell significantly only in the valsartan/hydrochlorothiazide group, which decreased from a median of 31.0 mg/min (IQR, 18.0–90.0) to 17.0 mg/min (IQR, 8.0–42.0) compared with amlodipine, which decreased

![Figure 1](image-url)
from a median of 25.0 μg/min (IQR, 14.0–60.0) to 22 μg/min (12.0–70.5) (P=0.03 between groups). Glycemic and lipid control remained stable during the 24 weeks of treatment, with no significant differences between the two groups at the study end (data not shown).

**Discussion**

Our study is the first to demonstrate that 24-week treatment with an ARB, valsartan, and hydrochlorothiazide significantly increases the plasma levels of soluble Klotho in patients with type II diabetes mellitus with albuminuria and relatively preserved renal function, an effect apparently independent of BP and associated with a reduction in serum phosphate.

Our data, from a secondary analysis, translate in humans the findings of earlier experimental studies demonstrating that angiotensin converting enzyme inhibitors or ARBs increase renal Klotho expression (5,14).

In a recent study conducted in 33 Asian patients with type II diabetes mellitus, 4-week treatment with losartan significantly increased soluble Klotho levels compared with an angiotensin converting enzyme inhibitor, quinapril (15). In the losartan-treated group, the rise in soluble Klotho was paralleled by a reduction in albuminuria (15). However, in this 4-week crossover study, both renin-angiotensin system (RAS) inhibitors were dosed submaximally (50% of maximum dose) and used in combination with other antihypertensive agents in some patients. Furthermore, phosphate, calcium, FGF-23, and Ao-PWV were not measured and albuminuria was determined from a single spot urine sample rather than a timed collection. Surprisingly, the authors reported that, in contrast to other studies, quinapril did not result in a significant reduction in BP or albuminuria (15,16).

Most clinical and laboratory studies in this field demonstrate that raised levels of soluble Klotho (measured by the same assay we utilized) are associated with reduced cardiovascular and renal risk (4). By contrast, renal impairment is characterized by a state of low levels of soluble Klotho (4).

Although previous clinical studies included healthy participants, patients with diabetes, and patients with varying severity of renal impairment (stage 1–5 CKD), the levels of soluble Klotho were not studied in detail in patients with type II diabetes mellitus, albuminuria, and relatively preserved renal function (all had an eGFR >45 ml/min per 1.73 m² and only 3 of 76 patients had an eGFR <60 ml/min per 1.73 m²) such as in this study. Recent studies in patients with more advanced kidney disease reported conflicting data. Akimoto et al. measured 24-hour urinary Klotho in patients with stage 1–5 CKD (60% had chronic GN as the cause of CKD, and only 16% had CKD caused by diabetic renal disease) and noted that urine Klotho levels and soluble Klotho levels were both significantly higher in stage 1 CKD compared with stage 4 and stage 5 CKD (17). In a multiple regression analysis, eGFR was independently associated only urinary excreted Klotho (17). Shimamura et al. reported higher levels of soluble Klotho in stage 1 CKD compared with stage 2 CKD and stages 3–5 in 292 patients, 10% of whom had diabetic renal disease (12). In contrast, Devaraj et al. demonstrated that nondiabetic participants with renal dysfunction (defined as serum creatinine >2 mg/dl) had higher soluble Klotho levels compared with participants with preserved renal function (18).

There are emerging data that soluble Klotho is an independent risk factor for cardiovascular disease. In a longitudinal study of 804 community-dwelling adults aged >65 years, higher levels of soluble Klotho were independently associated with lower cardiovascular risk and decreased all-cause mortality (13).

Soluble Klotho exerts vascular-renal protective effects independent of the transmembrane form that regulates phosphate excretion in the distal tubules in conjunction with FGF-23 (19). In experimental models of CKD, endogenous stimulation of soluble Klotho or its exogenous replacement can slow down the progression of renal dysfunction, reduce proteinuria, and prevent the vascular calcification induced by high levels of phosphate (2,4). Importantly, soluble Klotho may induce phosphaturia by FGF-23–independent mechanisms (2,4).

In patients with albuminuria, high phosphate levels, even within the normal range, are known to promote progression of renal disease and to attenuate the renoprotective effect of RAS inhibitors (20). Increasing evidence from *in vitro*, clinical, and epidemiologic studies indicates that elevated serum phosphorus levels *per se* are associated with vascular calcification and cardiovascular mortality (21).

We observed a significant reduction in serum phosphate with RAS blockade in our study, which negatively correlated with changes in soluble Klotho. This correlation (*R*=0.41; *P*=0.07), however, did not reach the conventional level of statistical significance. Because soluble Klotho has a known phosphaturic action, our results provide support to the assay we used, which is important because some uncertainty currently exists regarding the validity of soluble Klotho assays.

The mechanisms explaining our results need to be further investigated. Our results may be explained by increased renal expression of Klotho and its cleavage process; however, this needs to be confirmed in further studies. The assay we used detects soluble (cleaved) Klotho (130 kD) in the circulation. A smaller fragment of 68–70 kD, of unknown significance, is also present in the circulation but is not detected by the assay we utilized.

It is established that increased oxidative stress reduces the expression of Klotho and we speculate that a reduction in oxidative stress with valsartan may help explain, at least in part, our results because RAS blockade is known to reduce reactive oxygen species and inhibit pathways that promote oxidative stress (22). Because we did not directly measure changes in oxidative stress, further studies are needed to confirm our hypothesis/speculation.

We added a thiazide diuretic, hydrochlorothiazide, to ensure equivalent BP control in both study arms of our trial. Although there is no current evidence that thiazide diuretics affect renal Klotho expression, the possibility of an effect of hydrochlorothiazide on this protein, which is expressed in the distal renal tubules, cannot be excluded because we did not measure the levels of Klotho before hydrochlorothiazide was added to valsartan.
Thiazide diuretics are known to increase serum calcium levels and reduce urinary calcium excretion (23). We did not measure urinary calcium excretion in our study so an effect of hydrochlorothiazide on this measure cannot be excluded; however, we did not note any significant change in serum calcium levels with valsartan/hydrochlorothiazide treatment.

Thiazide diuretics do not demonstrate the BP-independent pleiotropic benefits observed with RAS blockers (9,24,25). Moreover, the salt and water depletion that would ensue from thiazide treatment activate the RAS and the autonomic nervous system (26). Therefore, the concomitant use of an antihypertensive agent like hydrochlorothiazide would, if anything, result in an underestimation of the effects of valsartan treatment on Klotho.

We did not measure vitamin D, a negative regulator of the RAS (27). Interestingly, recent data suggest that vitamin D may have cardioprotective effects by restoring Klotho levels (28). We also did not measure parathyroid hormone (PTH) levels or fractional excretion of phosphate (FEPi) in our patients. There are limited data on the effects of RAS blockade on PTH and FEPi. In healthy participants, infusion of AngII increases PTH secretion; however, no change in FEPi was reported in this study (29). In 16 children and young adults with T1DM and microalbuminuria, enalapril treatment decreased FEPi; however, to our knowledge, there are no data available in patients with type II diabetes mellitus such as those we studied (30). The effects, if any, of calcium channel blockers on FEPi or PTH have also not been studied in patients with type II diabetes mellitus.

We did measure levels of FGF-23, another important phosphaturic hormone, but we did not observe a significant difference in FGF-23 levels between treatment groups or a correlation between FGF-23 and phosphate or Klotho levels.

In our cohort of patients with type II diabetes mellitus and relatively preserved renal function, we did not observe any significant associations between soluble Klotho and changes in BP, arterial stiffness, and albuminuria. However, our study was not designed to test these associations and our sample size may not have been large enough. In an observational study of 114 Japanese patients with CKD where >50% of participants had an eGFR <45 ml/min per 1.73 m², the authors noted a significant association between low Klotho levels and raised arterial stiffness and markers of atherosclerosis (11). However, only 11% of participants had diabetes and the authors used ankle-brachial pulse wave velocity to measure arterial stiffness, rather than Ao-PWV, which is the recognized gold standard technique (31).

In patients with type II diabetes mellitus and albuminuria, RAS blockade results in cardiorenal protection independently of BP changes (32). In our study, the RAS blocker valsartan significantly increases soluble Klotho levels and reduces serum phosphate, effects that appear to be independent of its BP-lowering actions. These results, which need to be confirmed in larger studies, suggest that elevations in soluble Klotho levels may at least in part contribute to the BP-independent benefits observed with RAS blockers in patients with type II diabetes mellitus and albuminuria.

Acknowledgments
We thank the study participants and research nurses, without whom this work would not have been possible.

Some of this work was supported by a grant from Novartis Pharma AG (Basel, Switzerland).

Disclosures
None.

References


Received: March 7, 2013 Accepted: June 3, 2013

J.K. and G.M. contributed equally to this work.

Published online ahead of print. Publication date available at www.cjasn.org.